

***National Agency For The Safety Of Medicine And Health Products***

CERTIFICATE NUMBER: **2023\_HPFP\_PT\_005**

**CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER** <sup>1,2</sup>

**Part 1**

Issued following an inspection in accordance with :  
Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:

The manufacturer: ***Avista Pharma Solutions Inc.***

Site address: ***104 Gold Street, Agawam, MA, 01001-3807, United States***

OMS Organisation Id. / OMS Location Id.: ***ORG-100016287 / LOC-100025064***

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 19(3) of Regulation 726/2004/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2022-12-14**, it is considered that it complies with:

- The principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572 and Commission Delegated Regulation (EU) 2017/1569 <sup>3</sup>

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

<sup>1</sup>The certificate referred to in paragraph Art. 111(5) of Directive 2001/83/EC, shall also be required for imports coming from third countries into a Member State.

<sup>2</sup>Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

<sup>3</sup>These requirements fulfil the GMP recommendations of WHO.

## Part 2

Human Medicinal Products	
<b>1 MANUFACTURING OPERATIONS</b>	
<b>1.6</b>	<b>Quality control testing</b>
	<i>1.6.4 Biological</i>

Clarifying remarks (for public users)

*Legal basis for inspection: EU GMP Part IV -- This certificate relates to LUMEVOQ®, suspension for injection --- 1.6.4 :limited to bacterial endotoxin testing --- Signatory: Mrs Florence Descamps-Delesalle, head of the pharmaceutical product inspection and counterfeiting fight department--- The ANSM does not issue paper copies of good practice certificates.*

2023-03-03

Name and signature of the authorised person of the  
Competent Authority of France

-----  
*Confidential*  
*National Agency For The Safety Of Medicine And*  
*Health Products*  
Tel: *Confidential*  
Fax: *Confidential*